Users Stopping Weight-Loss Medications Regain Weight at a Quadrupled Rate Compared to Dieters

A recent study reveals that individuals who stop using popular slimming jabs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise regimens.

Research printed in a major health publication demonstrates that while overweight individuals frequently drop about a fifth of their body weight while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month once they quit.

"Individuals using these medications must be aware of the potential of rapid weight regain when the therapy is stopped," cautioned expert Dr. Susan Jebb.

That rate of recovery suggests a reversion to pre-treatment mass within about a year and a half.

Comparing Approaches

The study, which reviewed 37 of studies involving thousands of participants, contrasted the effects of the injectable medications with other pills.

The team note that people who shed pounds through lifestyle changes alone usually experience a less rapid creep back—around 100 grams monthly—once they finish.

Explaining the Quick Regain

Doctors believe the way of the jabs is key to understanding the accelerated weight return.

GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.

"Artificially providing GLP-1 levels far above than normal may cause the system to produce less of its own natural GLP-1, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a dietetics specialist.

"Stopping of this hormone supplement leads to appetite is unsuppressed, making binge eating much more probable."

A Chronic Disease?

Medical guidelines recommend the jabs for individuals with obesity-related health risks, alongside prescribed lifestyle changes.

Professionals contend that, given the significant potential of weight regain, the treatment should be considered ongoing.

This perspective is echoed by drug manufacturers, who state that the findings "highlight the persistent character of excess weight," comparing it to managing conditions like hypertension.

Patient Experiences

People who have stopped the medication describe a intense return of appetite.

"It felt as if a switch activating and I was suddenly starving," recalled one woman.

The struggle is exacerbated if individuals have not developed sustainable dietary or behavioural modifications during therapy.

Growing Use

Survey data indicate that millions of adults in the UK have tried these injections in the last 12 months, with interest remaining high.

• Use is more common among women compared to males.
• The middle-aged age group shows the greatest usage rates.
• Many access the drugs through private healthcare rather than public health services.

In conclusion, researchers stress that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone fix and maintained weight loss relies on integrated behavioural changes.